Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Home
/
update
/
details

ESMO 2024: GSK/iTeos's TIGIT Shows Promise in NSCLC, Intensifying the Competitive Landscape

NextEdge Admin

16 Sep 2024

2 min 31 sec

TIGIT inhibitors have faced a challenging path in the race to treat non-small cell lung cancer (NSCLC). At ESMO 2024, GSK and iTeos presented the first data on their TIGIT inhibitor, belrestotug, in combination with Jemperli (dostarlimab) for PD-L1-high NSCLC patients. The interim results from the Phase II GALAXIES Lung-201 trial, with a median follow-up of 7.3 months, showed promising efficacy. Across three dose levels of belrestotug (100, 400, and 1000mg), the combination nearly doubled the overall response rate (ORR) compared to dostarlimab monotherapy. Higher dose levels also demonstrated a 90% reduction in circulating tumor DNA (ctDNA).

Despite these encouraging findings, the analysis lacked insights into key secondary survival and durability endpoints, limiting the ability to assess how the combination compares to MSD’s Keytruda (pembrolizumab), a standard treatment in NSCLC. The trial’s small sample size (124 patients) further challenges the conclusions drawn.

The recommended Phase III dose (RP3D) of 400mg will be tested in the ongoing GALAXIES Lung-301 trial, comparing the belrestotug-Jemperli combination against Keytruda in 1,000 patients. In the smaller Phase II trial, the 400mg dose achieved a 59.4% ORR compared to 28.1% for Jemperli monotherapy, though no complete responses were reported in either arm. The combination also showed a median 94% decrease in ctDNA, indicating a deeper response.

However, the combination increased treatment-related adverse events (TRAEs) and immune-related adverse events (TR-irAEs). Belrestotug must demonstrate a clear overall survival benefit to challenge established PD-1 therapies and fend off competition from emerging antibody-drug conjugates and bispecific antibodies in the NSCLC treatment landscape.